Four drug makers brought in more than $14 billion in sales of COVID-19 treatments in 2021, but the lucrative, new market could be tempered in 2022.
Four drug makers brought in more than $14 billion in sales of COVID-19 treatments in 2021, but the lucrative, new market could be tempered in 2022.